---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302473"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2026-07-14T10:30:09+00:00"
generated_at: "2026-07-14T10:35:11.187336+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spero in-licenses SP001 anti-CD40L antibody from Innovent, secures $105M non-dilutive financing

## Summary
- In-licensed SP001 (anti-CD40L) from Innovent; Spero gets ex-China rights. Upfront $35M, milestones up to ~$1.05B, tiered royalties high single to mid-teen %.
- SP001 Phase 2-ready; Spero plans Phase 2 in IgG4-RD in Q2 2027. Innovent plans Phase 2 in SjD in China by early 2027.
- Secured $105M non-recourse notes from HCRx (KKR) at 10% interest, 9-year maturity, backed by Utebzi milestones/royalties from GSK.
- Cash runway extended into H2 2029; proceeds to fund SP001 development.
- Spero retains 35% of GSK proceeds after note repayment; HCRx gets 65% after note repayment.

## SEC filing metadata
- accession: 0001193125-26-302473
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2026-07-14T10:30:09+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/0001193125-26-302473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302473
- JSON: https://secwatch.observer/filing/0001193125-26-302473.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.